Yonsei University · Medicine
Professor Gi Hong Choi's research lab specializes in hepatobiliary and pancreatic surgery, with a strong focus on advancing minimally invasive surgical techniques—particularly robotic liver surgery—in the context of hepatocellular carcinoma (HCC) and liver cirrhosis. The lab investigates preoperative risk stratification, especially regarding portal hypertension, to optimize surgical outcomes and patient selection. It also evaluates the role of adjuvant therapies such as transarterial chemoembolization (TACE) in resectable HCC, aiming to clarify their impact on survival and recurrence patterns.
Figures are computed from collected data and may differ slightly.
Since the robotic surgical system was first introduced in 2005, the number of robotic surgery has been gradually increasing in Korea. The proportion of general robotic surgery is relatively higher compared to the western countries, but robotic liver resection is one of the most complex procedures among robotic general surgery. In this article, we introduce the development of robotic liver resection in Korea and describe our standardized techniques. The current data on robotic liver resection in
In Child-Pugh A cirrhotic patients, the presence of clinically significant PHT was significantly associated with post-operative hepatic decompensation and poor prognosis after resection of HCC. However, in patients with clinically significant PHT, those with single nodular tumours lacking gross vascular invasion may be good surgical candidates.
Preoperative TACE did not significantly improve the disease-free survival or the pattern of recurrence after curative resection of HCC. Even though this study is a retrospective analysis, preoperative TACE cannot be recommended as a routine procedure before hepatectomy for a resectable HCC.
Open papers in the app to read, cite, and organize with AI.
